Stapokibart
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Stapokibart
- cm 310
- cm 310 anti il 4r igg4 monoclonal antibody
- Cm-310
- CM-310 (Anti-IL-4R IgG4 monoclonal antibody)
- cm310
- CM310
- Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
- immunoglobulin g4 227 proline anti human interleukin 4 receptor subunit α human mus musculus monoclonal cm310 γ4 chain disulfide with human mus musculus monoclonal cm310 κ chain dimer
- stapokibart
- Stapokibart
- Stapokibart (CM310)
- stapokibart [INN]
- Stapokibart [WHO-DD]
- Stapokibart injection
- Stapokibart Injection
- stapokibart inn
- stapokibart who dd
- CAS registry numbers
- 2734715-10-5
- ChEMBL ID
- CHEMBL5095324
- FDA ingredient codes (UNII)
- L2REN9TU2D
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- stapokibart
- Type
- Antibody
- Drug name stem
- -bart
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- Interleukin-4 receptor subunit α
- Gene symbol
- IL4R
- Protein identifier
- P24394
- Median affinity
- 9.4
- Affinity units
- pIC50
- Action
- Binding
- Action type
- Binding
- Target
- Interleukin-4 receptor subunit α
- Gene symbol
- IL4R
- Protein identifier
- P24394
- Median affinity
- 9.6
- Affinity units
- pKd
- Primary target
- Yes
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003956
- Subject identifier
- D006255
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005854
- Subject identifier
- D006255
- Condition
- Pruritus
- Highest recorded phase
- 2
- Condition identifier
- HP:0000989
- Subject identifier
- D011537
- Condition
- Asthma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Inflammation
- Highest recorded phase
- 2
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0003956
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005854
- Highest recorded phase
- 3
- Condition identifier
- EFO_1002029
- Highest recorded phase
- 2
- Condition identifier
- EFO_1002029
- Highest recorded phase
- 3
- Condition identifier
- HP_0000989
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005324
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0010150
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011786
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015301
- Condition identifier
- MONDO_0017287
- Condition identifier
- MONDO_0019082
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0026045
- Highest recorded phase
- 3
- Condition identifier
- MP_0001845
- NCT04805411
- NCT04893707
- NCT04893941
- NCT05265923
- NCT05579925
- NCT05715320
- NCT06116565
- NCT06162507
- NCT06277765
- NCT05186909
- NCT05761028
- NCT05452343
- NCT05908032
- NCT05908721
- NCT06171074
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVSTISSGGSYTNYADSVKGRFTISRDNVKNTLYLQMNSLRAEDTAVYYCARATARATEFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGNTLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 296 $ 296''
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 133-214' $ 133''-214''' $ 134'-194' $ 134'''-194''' $ 146-202 $ 146''-202'' $ 225-225'' $ 228-228'' $ 260-320 $ 260''-320'' $ 366-424 $ 366''-424''
Related records
Trials (38)
- A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
- A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma
- A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
- A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
- A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）
- A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
- A Study of CM310 in Subjects With Chronic Pruritus
- A Study of CM310 in Subjects With Moderate to Severe Asthma
- A Study of CM310 in Subjects With Moderate to Severe Asthma
- A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
- A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
- A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
- A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
- Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis
- Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
- Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
- Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps
- Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects
- Study of CM310 in Adolescent Subjects With Atopic Dermatis
In development for (5)
- Allergic rhinitis Phase 3
- Asthma Phase 2
- Atopic eczema Phase 3
- Prurigo nodularis Phase 3
- Seasonal allergic rhinitis Phase 3
Other linked conditions (3)
- Chronic obstructive pulmonary disease
- Immunoglobulin G4-related sclerosing disease
- Primary cutaneous amyloidosis